Chloroquine and hydroxychloroquine as potential therapies against COVID-19
Yewange Sangmeshwar, Deshpande Renuka, Nikhil Waghmare, Vidyasagar Gali, Shyamlila B. Bavage, Nandkishor B. Bavage
chloroquine clinical research clinical trials corona virus in COVID-19 disease & medicine hydroxychloroquine malaria nut shell SARS-CoV-2
The desperate search to find effective treatments for coronavirus disease 2019 (COVID-19), 2 generic drugs, used largely by rheumatologists and dermatologists to treat immune-mediated diseases, have entered the spotlight. The antimalarials hydroxychloroquine (HCQ) and chloroquine (CQ) have demonstrated antiviral activity against severe acute respiratory syndrome–coronavirus 2 (SARS–CoV-2) in vitro and in small, poorly controlled or uncontrolled clinical studies (1–3). Normally, such research would be deemed hypothesis-generating at best. Here, we try to provide guidance regarding clinical decision making both for patients with COVID-19 and those with immune-mediated conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and strategies to mitigate further harm to these patients.